2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Young A, Lacerda A, Paik J, Popova V, Fu D. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. The International Journal Of Neuropsychopharmacology 2025, 28: pyaf027. PMID: 40319349, PMCID: PMC12143125, DOI: 10.1093/ijnp/pyaf027.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionSustained 3Oral antidepressantNon-treatment-resistant major depressive disorderMontgomery-Asberg Depression Rating ScaleTreatment-resistant depression treatmentEsketamine nasal sprayDepression Rating ScaleMajor depressive disorderLong-term extension studySafety of esketamineLong-term safetyRate of relapseMontgomery-AsbergDepressive disorderDepression severityEsketamine dosesExtension studySuicide riskDepressive symptomsEsketamineRating ScaleMaintenance treatmentAdverse eventsLong-term treatmentEffect of Esketamine on Depressive Symptoms in Adolescents with Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study
Kosik-Gonzalez C, Fu D, Chen L, Lane R, Bloch M, DelBello M, Moreno C, Drevets W, Canuso C. Effect of Esketamine on Depressive Symptoms in Adolescents with Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 2025 PMID: 40058488, DOI: 10.1016/j.jaac.2025.02.015.Peer-Reviewed Original ResearchChildren's Depression Rating Scale-RevisedMajor depressive disorderDepressive disorderDepressive symptomsEsketamine dosesSymptoms of major depressive disorderCDRS-R total scoreEsketamine nasal sprayEvidenced-based psychotherapySeverity of suicidalityImprove depressive symptomsReducing depressive symptomsEffects of esketamineIntentional self-injuryImminent riskIntranasal esketamineOral antidepressantSelf-injurySuicidal ideationEnd-point changesAnalysis of covarianceScale-RevisedBetween-group differencesEsketamineTotal score
2024
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression
Chepke C, Shelton R, Sanacora G, Doherty T, Tsytsik P, Parker N. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression. The International Journal Of Neuropsychopharmacology 2024, 27: pyae058. PMID: 39611487, PMCID: PMC11635826, DOI: 10.1093/ijnp/pyae058.Peer-Reviewed Original ResearchEsketamine nasal sprayRespiratory depressionAdverse eventsTreatment of treatment-resistant depressionStandardized Medical Dictionary for Regulatory ActivitiesPhase 3 clinical trialsTreatment-resistant depressionMitigation strategy programCentral respiratory depressionTreatment of depressive symptomsAcute suicidal ideationPostdose observation periodNo adverse eventsMedical Dictionary for Regulatory ActivitiesOral antidepressantNasal sprayCases meeting criteriaDepressive disorderPostmarketing settingPostapproval dataSuicidal ideationDepressive symptomsOxygen saturationPulse oximetryCase definitionEffect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies
Morrison R, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, Lane R, Cooper K, Sanacora G, Maruff P, Drevets W. Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. The International Journal Of Neuropsychopharmacology 2024, 27: pyae046. PMID: 39514643, PMCID: PMC11561565, DOI: 10.1093/ijnp/pyae046.Peer-Reviewed Original ResearchEsketamine nasal sprayTreatment-resistant depressionLong-term maintenance treatmentMADRS scoreOral antidepressantHopkins Verbal Learning Test-RevisedMaintenance treatmentCognitive test batteryEffects of esketamineGroup mean performanceFollow-up assessmentMild to moderate impairmentDepression severityTest-RevisedCogState batteryCognitive performancePsychomotor functionTest batteryCognitive testsCognitionEsketamineNasal sprayEffect sizeDepressionEffects of short-term
2023
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Castro M, Wilkinson S, Al Jurdi R, Petrillo M, Zaki N, Borentain S, Fu D, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs 2023, 37: 715-723. PMID: 37558912, PMCID: PMC10439056, DOI: 10.1007/s40263-023-01026-3.Peer-Reviewed Original ResearchConceptsEsketamine nasal spraySUSTAIN 1Nasal spraySecond inductionMaintenance treatmentMADRS response ratesTreatment-emergent AEsDepression rating scoresNew safety signalsTreatment-resistant depressionTime of relapseLong-term treatmentLong-term trialsEligible patientsOral antidepressantsRemission rateStable remissionSubgroup analysisChronic illnessSafety signalsInterim analysisDepressive symptomsPatientsResponse rateRemissionLong-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine treatmentMontgomery-Åsberg Depression Rating Scale (MADRS) total scoreCommon treatment-emergent adverse eventsLong-term extension studyTreatment-emergent adverse eventsEsketamine nasal sprayMean cumulative durationLong-term tolerabilityNew safety signalsHealth-related qualityMaintenance of responseLong-term treatmentMajor depressive disorderLong-term safetyPhase 3Scale total scoreMaintenance phaseOral antidepressantsData cutoffAdverse eventsMaintenance treatmentSustained efficacyEligible participantsDepression ratingsPredictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
Turkoz I, Nelson J, Wilkinson S, Borentain S, Macaluso M, Trivedi M, Williamson D, Sheehan J, Salvadore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research 2023, 323: 115165. PMID: 37019044, DOI: 10.1016/j.psychres.2023.115165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine nasal sprayNasal sprayDay 28Day 8Clinical Global Impression-Severity scoreCGI-S scoresCurrent depressive episodePredictors of responsePlacebo nasal sprayIdentification of predictorsOral antidepressantsBaseline patientAcute trialPooled analysisDepressive episodeRemissionPsychiatric characteristicsPatientsSignificant anxietyYounger ageTreatment assignmentPotential predictorsPhase 3PredictorsLong-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study
Young A, Zaki N, Chen N, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Lacerda A, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study. Neuroscience Applied 2023, 2: 102450. DOI: 10.1016/j.nsa.2023.102450.Peer-Reviewed Original Research
2019
POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. American Journal Of Geriatric Psychiatry 2019, 27: s140-s141. DOI: 10.1016/j.jagp.2019.01.094.Peer-Reviewed Original ResearchTreatment-resistant depressionMADRS total scoreOpen-label safety studyEsketamine nasal sprayLabel Safety StudyLS mean differenceNew oral antidepressantDuration of treatmentOnset of depressionInterim analysisOral antidepressantsYears of ageNasal sprayPrimary analysisElderly patientsTotal scoreMean changeLarge phase 3 studiesDay 25Mean differenceStage 2Safety studiesPrimary efficacy endpointPhase 3 studyUnexpected safety concernsEFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. American Journal Of Geriatric Psychiatry 2019, 27: s139-s140. DOI: 10.1016/j.jagp.2019.01.093.Peer-Reviewed Original ResearchEsketamine nasal sprayTreatment-emergent adverse eventsTreatment-resistant depressionPlacebo nasal sprayCommon treatment-emergent adverse eventsTreatment of TRDMADRS total scoreElderly patientsNasal sprayOral antidepressantsTotal scoreDay 28Montgomery-Åsberg Depression Rating Scale (MADRS) total scoreBaseline MADRS total scoreDouble-blind treatment phasePre-specified subgroup analysisFirst large clinical trialJanssen ResearchMean patient ageSafety of esketamineLarge clinical trialsNew safety concernsActive-controlled studyScale total scoreYears of ageEfficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression. European Neuropsychopharmacology 2019, 29: s355-s356. DOI: 10.1016/j.euroneuro.2018.11.548.Peer-Reviewed Original ResearchLong-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study
Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study. European Neuropsychopharmacology 2019, 29: s44-s45. DOI: 10.1016/j.euroneuro.2018.11.1016.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply